Labetuzumab

Drug Profile

Labetuzumab

Alternative Names: Anti-CEA monoclonal antibody MN 14; CEA-Cide; hCEA; hMN-14; IMMU-100; IMMU-14; Monoclonal antibody MN-14

Latest Information Update: 19 Jan 2007

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Immunomedics
  • Class Antineoplastics; Monoclonal antibodies
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Ovarian cancer; Small cell lung cancer; Pancreatic cancer
  • New Molecular Entity Yes

Highest Development Phases

  • No development reported Breast cancer; Colorectal cancer; Ovarian cancer

Most Recent Events

  • 05 Jun 2003 Data presented at the 39th Annual Meeting of the American Society of Clinical Oncology (ASCO-2003) have been added to the Cancer pharmacodynamics section
  • 04 Nov 2002 Preclinical data from a media release have been added to the Cancer pharmacodynamics section
  • 17 Aug 1999 CEA-Cide has Orphan Drug status for ovarian cancer in the USA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top